Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P36404
UPID:
ARL2_HUMAN
Alternative names:
-
Alternative UPACC:
P36404; G3V184; Q9BUK8
Background:
ADP-ribosylation factor-like protein 2 is a pivotal small GTP-binding protein, transitioning between GDP-bound and GTP-bound forms, influenced by guanine nucleotide exchange factors and GTPase-activating proteins. It plays a crucial role in microtubule formation, centrosome integrity, and mitochondrial function, and is involved in various cellular processes including cell cycle progression and regulated secretory pathways.
Therapeutic significance:
The protein's association with Microcornea, rod-cone dystrophy, cataract, and posterior staphyloma 1 highlights its potential in ocular disorder therapies. Understanding the role of ADP-ribosylation factor-like protein 2 could open doors to potential therapeutic strategies.